Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00893984 · ClinicalTrials.gov registry record · Phase 4
Alternative in Beta Blocker Intolerance: The ABBI Trial
A Phase 4 study, sponsored by Minneapolis Heart Institute Foundation.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT00893984 is a Phase 4 study that was terminated before completion, run by Minneapolis Heart Institute Foundation. The registered enrollment target is 6 participants.
The verdict
NCT00893984, a Phase 4 study, was terminated before completion, sponsored by Minneapolis Heart Institute Foundation.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
In this study the investigators will assess the tolerance of Nebivolol (Bystolic) in cardiovascular patients who are not able to tolerate conventional beta blockers. A side effect profile will be tracked and compared with previous beta blocker use. The investigators hypothesize that Bystolic will be tolerated by many patients who are intolerant of conventional blockers.
Interventions
- DRUG Nebivolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00893984
The ClinicalTrials.gov registry entry for NCT00893984 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Minneapolis Heart Institute Foundation, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nebivolol is the first listed.
NCT00893984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00893984 about?
NCT00893984 is a clinical study titled "Alternative in Beta Blocker Intolerance: The ABBI Trial". In this study the investigators will assess the tolerance of Nebivolol (Bystolic) in cardiovascular patients who are not able to tolerate conventional beta blockers. A side effect profile will be tracked and compared with previous beta blocker use. The investigators hypothesize that Bystolic will b...
What is the current status of trial NCT00893984?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2009-05. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00893984?
The interventions under investigation include: Nebivolol (DRUG).
Who is sponsoring clinical trial NCT00893984?
This trial is sponsored by Minneapolis Heart Institute Foundation, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.